Inavolisib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 3mg, 9mg
Reference Brands: Itovebi (USA/EU)
Category: Critical Care
Inavolisib is a targeted oral PI3K-alpha inhibitor used in combination with palbociclib and fulvestrant for treating PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer. It not only inhibits the mutated PI3Kα enzyme but also promotes its degradation, selectively acting on cancer cells with PIK3CA mutations. The drug has shown strong efficacy in prolonging progression-free survival in clinical trials. Inavolisib is available in Tablets and strengths such as 3mg, 9mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Inavolisib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Inavolisib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Inavolisib is used in combination with palbociclib and fulvestrant to treat adults with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer that carries a PIK3CA mutation. It is specifically indicated for patients whose disease has become resistant to endocrine therapy.
Inavolisib is made from the active substance inavolisib, a selective PI3K-alpha inhibitor. It works by blocking and degrading the mutant PI3K-alpha enzyme, which helps stop cancer cell growth in tumors driven by PIK3CA mutations.
The trade name of inavolisib is Itovebi.
Inavolisib (Itovebi) is developed and manufactured by Roche/Genentech.
The generic name is inavolisib.
The brand name is Itovebi.
Inavolisib is manufactured by Roche/Genentech at their approved global pharmaceutical production facilities, depending on regional supply requirements.
Related Products
Somatrogon‑Ghla
Strength:
24 mg/1.2 mL, 60 mg/1.2 mL
Form: injection (prefilled syringe)
Reference Brands: Ngenla (USA)
View Details
Methimazole
Strength:
5 mg, 10 mg
Form: Tablets
Reference Brands: Tapazole (USA), Northyx (USA)
View DetailsQuick Response Guaranteed | Verified Suppliers
